We read with interest the article of Booyens et al. discussing the risk of venous thromboembolism (VTE) with hormonal replacement therapy (HRT) [
]. This article nicely summarized over 80 years of HRT development for the relief of menopausal symptoms, but we observed some approximations which, in our opinion, need to be highlighted.
- Booyens R.M.
- Engelbrecht A.-M.
- Strauss L.
- Pretorius E.
To clot, or not to clot: the dilemma of hormone treatment options for menopause.
Thromb. Res. 2022; 218: 99-111https://doi.org/10.1016/j.thromres.2022.08.016
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Thrombosis Research
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- To clot, or not to clot: the dilemma of hormone treatment options for menopause.Thromb. Res. 2022; 218: 99-111https://doi.org/10.1016/j.thromres.2022.08.016
- Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause.Expert. Rev. Clin. Pharmacol. 2022; 15: 121-137
- Oral contraceptives and venous thromboembolism: focus on testing that may enable prediction and assessment of the risk.Semin. Thromb. Hemost. 2020; 46: 872-886
- Biomarkers, menopausal hormone therapy and risk of venous thrombosis: the Women's Health Initiative.Res. Pract. Thromb. Haemost. 2018; 2: 310-319
- Estetrol (E4) is a native fetal estrogen that does not modify coagulation markers in postmenopausal women and maintains sensitivity to activated protein C (APC).Maturitas. 2021; 152: 69https://doi.org/10.1016/j.maturitas.2021.08.013
- Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need.Clin. Chem. Lab. Med. 2020; 58: 294-305
- Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters.Contraception. 2020; 102: 396-402
- Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women.Br. J. Haematol. 2002; 119: 1017-1023
- Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.Arterioscler. Thromb. Vasc. Biol. 2003; 23: 1116-1121
- Low thrombin generation in users of a contraceptive containing estetrol and drospirenone.J. Clin. Endocrinol. Metab. 2022; (In press)https://doi.org/10.1210/clinem/dgac511
Published online: September 15, 2022
Accepted: September 12, 2022
Received in revised form: September 8, 2022
Received: September 6, 2022
Publication stageIn Press Journal Pre-Proof
© 2022 Elsevier Ltd. All rights reserved.